findmyKOL
Clinical trialNCT05927779UnknownPhase 1/PHASE2Interventional

Study of TFX06 in Women With Advanced Breast Cancer.

SponsorZhejiang Yangli Pharmaceutical Technology Co., Ltd.Enrollment74ER+, HER2- Advanced Breast CancerMetastatic Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • the 1st Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

    Recruiting
  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

    jian zhang, phD
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Apr 2023
Primary completion
30 Dec 2024
Completion
30 Apr 2025
Last update posted
3 Jul 2023
Registered enrollment
74
Registry id
NCT05927779

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.